Table 1.
Comparative analyses results of variables between PSA persistence group and no PSA persistence group
| PSA persistence (n=52) | No PSA persistence (n=44) | p | |
|---|---|---|---|
| Age, years, mean (SD) | 66.9 (7.0) | 67.1 (6.4) | 0.892 |
| BMI, kg/m2, mean (SD) | 23.9 (2.5) | 24.2 (2.4) | 0.509 |
| Preoperative PSA, ng/mL, mean (SD) | 30.6 ± 29.1 | 30.5 ± 37.2 | 0.996 |
| PSA at 6 weeks, ng/mL, mean (SD) | 3.2 ± 9.1 | 0.02 ± 0.03 | 0.014 |
| Operative type, n (%) | 0.476 | ||
| Open | 36 (69.2) | 28 (63.6) | |
| Robotic | 16 (30.8) | 16 (36.4) | |
| Pathologic stage, n | 0.704 | ||
| ≤ pT2 | 3 (6.1%) | 4 (9.1%) | |
| ≥ pT3 | 49 (93.9%) | 40 (90.9%) | |
| Pathologic GS, n | 0.517 | ||
| 7 | 29 (55.3%) | 28 (64.3%) | |
| ≥8 | 23 (44.7%) | 16 (35.7%) | |
| Total number of removed LNs, mean (SD, range) | 13.8 (7.8, 2-41) | 13.8 (5.9, 3-29) | 0.992 |
| Total number of positive LNs, mean (SD, range) | 2.9 (3.4, 1-18) | 1.8 (1.2, 1-5) | 0.037 |
| Total number of positive LNs ≥ 2 | 29 (55.8%) | 21 (47.7%) | 0.432 |
| LN density, mean (SD) | 0.25 (0.24) | 0.15 (0.10) | 0.012 |
| ECE, yes | 41 (78.8%) | 36 (81.8%) | 1.000 |
| SVI, yes | 33 (63.5%) | 29 (65.9%) | 1.000 |
| PSM, yes | 41 (79.6%) | 32 (72.7%) | 0.472 |
| LVI, yes | 23 (44.2%) | 21 (47.7%) | 0.767 |
| Adjuvant therapy, n | 0.934 | ||
| None | 7 (14.3%) | 9 (20.0%) | |
| ADT only | 34 (64.3%) | 26 (60.0%) | |
| Radiotherapy only | 0 (0%) | 0 (0%) | |
| ADT + Radiotherapy | 11 (21.4%) | 9 (20.0%) | |
| BCR, yes | 10 (19.2%) | 15 (34.1%) | 0.159 |
| Radiographic PFS, yes | 16 (30.8%) | 5 (11.4%) | 0.022 |
ADT: androgen deprivation therapy, BMI: body mass index, ECE: extracapsular extension, GS: Gleason score, LN: lymph node, LVI: lymphovascular invasion, PFS: progression-free survival, PSM: positive surgical margin, SVI: seminal vesicle invasion